Loading...
01/11 03:38
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary shows positive revenue and gross margin guidance, strong clinical trial results, and AI tool launches. Despite some uncertainties in the Q&A, such as lack of specific milestones in partnerships and unclear responses, the raised guidance and strategic initiatives suggest a positive outlook. The positive sentiment is further supported by optimistic growth expectations and strategic focus on RNS expansion. Given these factors, the stock price is likely to experience a positive movement in the short term.
Total Revenue $27.4 million, a 30% year-over-year growth compared to $21.1 million in the prior year quarter. This growth was primarily driven by RNS initial implants and broad-based growth across geographies, customers, and programs.
RNS Revenue $22.6 million, representing growth of 31% year-over-year. Growth was driven by increased adoption and utilization, enhanced commercial leadership, improved referral management, and contributions from Project CARE and direct-to-consumer efforts.
Gross Margin 77.4%, compared to 73.2% in the prior year quarter. The increase was due to improved manufacturing efficiency, favorable pricing, and leverage as the company scaled.
Operating Expenses $23.8 million, up from $19.7 million in the prior year quarter, reflecting higher sales performance, variable compensation, and investments in R&D and sales and marketing.
Adjusted EBITDA Positive $0.1 million, compared to negative $1.6 million in the prior year quarter. This improvement reflects disciplined expense management, mix improvement, and increased efficiency in commercial and manufacturing operations.
Net Loss $3.5 million, compared to $5.5 million in the prior year period. The improvement was driven by higher revenue and gross margins, partially offset by increased operating expenses.
Free Cash Flow Negative $2 million, compared to negative $1.8 million in the prior year quarter. The change reflects higher revenue and gross margins, offset by increased inventory for the DIXI product line.
RNS System: Achieved record revenue of $22.6 million, a 31% year-over-year growth. Broad-based growth across geographies, customers, and programs. Enhanced commercial leadership and improved referral management contributed to higher procedural volumes.
Seizure iEEG AI software tool: Submitted to the FDA as the first of a suite of planned NeuroPace AI applications. Designed to improve clinical outcomes using proprietary iEEG data and AI development efforts.
Geographic and customer expansion: Broad-based growth in RNS adoption across geographies and customer bases. Increased utilization in Level 4 centers and growing contributions from Level 3 and community centers.
Direct-to-consumer efforts: Increased contributions from direct-to-consumer marketing efforts, supporting broader adoption of the RNS System.
Revenue growth: Total revenue reached $27.4 million, a 30% year-over-year growth. Raised full-year revenue guidance to $97-$98 million, reflecting 21%-23% growth.
Gross margin improvement: Gross margin increased to 77.4% from 73.2% in the prior year. RNS System gross margin exceeded 80%.
Adjusted EBITDA: Achieved positive adjusted EBITDA for the first time in company history, reflecting scalability and disciplined expense management.
NAUTILUS study: Completed a pre-submission meeting with the FDA. Plans to submit PMA supplement for NAUTILUS by year-end remain on track.
Pediatric indication expansion: Collaboration with FDA and NEST to finalize real-world evidence and protocol for pediatric indication. Submission timeline extended beyond 2025.
Strategic shift from DIXI products: Wind-down of DIXI product line by end of 2025 to focus solely on RNS System and potential FDA approval of expanded indications.
Regulatory Delays: The timeline for the pediatric indication submission has been extended beyond 2025 due to delays in aligning on the protocol and data set with the FDA and collaboration partner NEST. This could delay the expansion into the pediatric market.
Product Line Transition Risks: The wind-down of the DIXI product line and the strategic shift to focus solely on the RNS system may lead to operational challenges and potential revenue gaps during the transition period.
Dependency on FDA Approvals: The success of the NAUTILUS PMA supplement and the pediatric indication expansion is heavily dependent on FDA approvals. Any unfavorable decisions or delays could impact strategic growth plans.
Economic and Tariff Pressures: Incremental tariffs have impacted the gross margins of the DIXI product line, and similar economic pressures could affect future operations.
Operational Scalability: While the company has achieved positive adjusted EBITDA, maintaining scalability and operational efficiency as the business grows could pose challenges.
Market Adoption Challenges: Despite the growing recognition of the RNS system, achieving broader market adoption, especially in new indications like pediatric epilepsy, may take longer than anticipated.
NAUTILUS PMA Supplement Submission: NeuroPace plans to submit the PMA supplement for the NAUTILUS study to the FDA before the end of 2025. This submission is based on discussions with the FDA and a belief in the safety and effectiveness profile of the data.
Pediatric Indication Expansion: The company is working with the FDA and NEST to finalize the real-world evidence and protocol for a pediatric indication. However, the timeline for submission has been extended beyond 2025.
AI-Enabled Tools: NeuroPace has submitted its seizure iEEG AI software tool to the FDA, marking the first of a planned suite of AI applications aimed at improving clinical outcomes.
RNS System Development: The development pipeline focuses on enhancing on-device analytics, programming workflows, and connectivity to improve outcomes and support wider adoption.
Revenue Guidance for 2025: NeuroPace has raised its full-year revenue guidance to a range of $97 million to $98 million, reflecting 21% to 23% year-over-year growth. RNS System revenue is expected to be $20 million to $21 million in Q4 2025.
Gross Margin Guidance for 2025: The company has increased its full-year gross margin guidance to a range of 76% to 77%, up from the previous range of 75% to 76%. RNS System gross margin is expected to remain above 80%.
Operating Expenses for 2025: Total operating expenses are projected to range between $94 million and $95 million, reflecting a 16% to 18% year-over-year increase. This includes investments in next-generation products and clinical trials.
DIXI Product Line Wind-Down: The distribution agreement for DIXI products will wind down by the end of Q1 2026, with minimal sales expected in 2026. The company will focus solely on the RNS business and potential FDA approvals for expanded indications.
The selected topic was not discussed during the call.
The earnings call summary shows positive revenue and gross margin guidance, strong clinical trial results, and AI tool launches. Despite some uncertainties in the Q&A, such as lack of specific milestones in partnerships and unclear responses, the raised guidance and strategic initiatives suggest a positive outlook. The positive sentiment is further supported by optimistic growth expectations and strategic focus on RNS expansion. Given these factors, the stock price is likely to experience a positive movement in the short term.
The earnings call highlights strong financial performance with a 24% revenue increase, positive RNS sales growth, and a strategic focus on high-margin products. Despite a net loss, improved cash flow and sufficient liquidity are positive indicators. The Q&A section reveals confidence in growth targets, strong clinical data, and potential partnerships, boosting sentiment. However, a modest step-down in growth guidance and uncertainties around therapeutic partnerships slightly temper optimism. Overall, the positive aspects outweigh the concerns, suggesting a positive stock price reaction.
The earnings call summary indicates strong financial performance, with a 24% revenue increase and improved margins. Guidance for 2025 is optimistic, projecting 16-21% revenue growth. However, there are concerns about long-term borrowing risks and unclear management responses in the Q&A. Despite this, the positive trends in RNS sales, Project CARE, and gross margin improvements outweigh the negatives, suggesting a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
